Información del artículo
El Texto completo está disponible en PDF
References
[1.]
P.M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P.K. Whelton, J. He.
Global burden of hypertension: analysis of worldwide data.
Lancet, 365 (2005), pp. 217-223
[2.]
S. Wild, G. Roglic, A. Green, R. Sicree, H. King.
Global prevalence of Diabetes: estimates for the year 2000 and projections for 2030.
Diabetes Care, 27 (2004), pp. 1047-1053
[3.]
P.K. Whelton, J. He, L.J. Appel, J.A. Cutler, S. Havas, T.A. Kotchen, et al.
Primary prevention of hypertension: Clinical and public health advisory from the national high blood pressure education program.
JAMA, 288 (2002), pp. 1882-1888
[4.]
J.D. Curb, S.L. Pressel, J.A. Cutler.
Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension.
JAMA, 276 (1996), pp. 1886-1892
[5.]
F. Turnbull, B. Neal, C. Algert, J. Chalmers, N. Chapman, J. Cutler, et al.
Blood Pressure Lowering Treatment Trialists’ Collaboration Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus.
Arch Intern Med, 165 (2005), pp. 1410-1419
[6.]
R. Kunz, C. Friedrich, M. Wolbers, J.F.E. Mann.
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease.
Ann Intern Med, 148 (2008), pp. 30-48
[7.]
P.K. Whelton, J. Barzilay, W.C. Cushman, B.R. Davis, E. Iiamatchi, J.B. Kostis, et al.
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia.
Arch Intern Med, 165 (2005), pp. 1401-1409
[8.]
J.I. Barzilay, J.A. Cutler, B.R. David.
Antihypertensive medications and risk of diabetes mellitus.
Nephrol Hypertens, 16 (2007), pp. 256-260
[9.]
E.L. Gillespie, C.M. White, M. Kardas, M. Lindberg, C.I. Coleman.
The impact of ACE inhibitors or angiotensin II type I receptor blockers on the development of new-onset type 2 diabetes.
Diabetes Care, 28 (2005), pp. 2261-2266
[10.]
J.B. Kostis, A.C. Wilson, R.S. Freudenberger, N.M. Cosgrove, S.L. Pressel, B.R. Davis.
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.
Am J Cardiol, 95 (2005), pp. 29-35
[11.]
A.J. Zillich, J. Garg, S. Basu, G.L. Bakris, B.L. Carter.
Thiazide diuretics, potassium, and the development of diabetes: a quantitative review.
Hypertension, 48 (2006), pp. 219-224
[12.]
B.L. Carter, P.T. Einhorn, M. Brands, J. He, J.A. Cutler, P.K. Whelton, et al.
Thiazide-induced dysglycemia: Call for research from a working group from the National Heart, Lung and Blood Institute.
Hypertension, 52 (2008), pp. 30-36
[13.]
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38.
BMJ, 317 (1998), pp. 703-713
[14.]
R.R. Holman, K.P. Sanjoy, M.A. Bethel, H.A.W. Neil, D.R. Matthews.
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
N Engl J Med, 359 (2008), pp. 1565-1576
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
